Reliance Global Group has entered into a non-binding term sheet to acquire a majority equity position in Scentech, an Israeli diagnostics company developing artificial intelligence technologies for identifying disease-associated molecular signatures in human breath. The transaction is structured to achieve majority ownership through the achievement of performance-based clinical and regulatory milestones. This move marks the first strategic acquisition for Reliance's newly launched subsidiary, Ezra International Group, which focuses on investments in technology-enabled companies, including those in healthcare and data-driven platforms. Completion of the transaction remains subject to definitive agreements, due diligence, and customary closing conditions. Scentech's products are still under development and have not yet been clinically validated or approved for commercial use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reliance Global Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9621237-en) on January 07, 2026, and is solely responsible for the information contained therein.